{"id":"https://openalex.org/W2168026945","doi":"https://doi.org/10.1158/1535-7163.mct-10-0156","title":"Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)","display_name":"Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)","publication_year":2010,"publication_date":"2010-05-26","ids":{"openalex":"https://openalex.org/W2168026945","doi":"https://doi.org/10.1158/1535-7163.mct-10-0156","mag":"2168026945","pmid":"https://pubmed.ncbi.nlm.nih.gov/20501803","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3108331"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-10-0156","doi":"https://doi.org/10.1158/1535-7163.mct-10-0156","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0156","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/6/1485/1887052/1485.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/9/6/1485/1887052/1485.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055316719","display_name":"Hazem Edmond El-Osta","orcid":"https://orcid.org/0000-0003-1825-2815","observed_orcids":["https://orcid.org/0000-0003-1825-2815"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hazem El-Osta","raw_affiliation_strings":["Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":["Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliation: Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), The University of Texas, M.D. Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5053481267"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":2.6846,"has_fulltext":true,"cited_by_count":71,"citation_normalized_percentile":{"value":0.90660095,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"9","issue":"6","first_page":"1485","last_page":"1488"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.8827999830245972,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.8827999830245972,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.02979999966919422,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13314","display_name":"Lymphadenopathy Diagnosis and Analysis","score":0.021800000220537186,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castleman-disease","display_name":"Castleman disease","score":0.9929999709129333},{"id":"https://openalex.org/keywords/anakinra","display_name":"anakinra","score":0.9269999861717224},{"id":"https://openalex.org/keywords/interleukin-1-receptor-antagonist","display_name":"interleukin-1 receptor antagonist","score":0.9959999918937683},{"id":"https://openalex.org/keywords/interleukin-1","display_name":"interleukin-1","score":0.8539999723434448},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9929999709129333},{"id":"https://openalex.org/keywords/lymphoproliferative-disorders","display_name":"lymphoproliferative disorders","score":0.8790000081062317},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C2781228260","wikidata":"https://www.wikidata.org/wiki/Q415411","display_name":"Anakinra","level":3,"score":0.9635462164878845},{"id":"https://openalex.org/C149892131","wikidata":"https://www.wikidata.org/wiki/Q14914156","display_name":"Interleukin 1 receptor antagonist","level":5,"score":0.7983988523483276},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6185248494148254},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.6089822053909302},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5747609734535217},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4460929036140442},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4404152035713196},{"id":"https://openalex.org/C74172505","wikidata":"https://www.wikidata.org/wiki/Q194908","display_name":"Interleukin","level":3,"score":0.4320664405822754},{"id":"https://openalex.org/C2777977768","wikidata":"https://www.wikidata.org/wiki/Q15996698","display_name":"Interleukin-1 receptor","level":4,"score":0.4246845841407776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4232645630836487},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3717665374279022},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3475455641746521},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.2939833402633667}],"mesh":[{"descriptor_ui":"D001772","descriptor_name":"Blood Cell Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005871","descriptor_name":"Castleman Disease","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D005871","descriptor_name":"Castleman Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019788","descriptor_name":"Fluorodeoxyglucose F18","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049268","descriptor_name":"Positron-Emission Tomography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051598","descriptor_name":"Whole Body Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053590","descriptor_name":"Interleukin 1 Receptor Antagonist Protein","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-10-0156","doi":"https://doi.org/10.1158/1535-7163.mct-10-0156","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0156","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/6/1485/1887052/1485.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20501803","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20501803","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Case Reports"},{"id":"pmh:oai:europepmc.org:2130308","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3108331","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3108331","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3108331","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-10-0156","doi":"https://doi.org/10.1158/1535-7163.mct-10-0156","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0156","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/6/1485/1887052/1485.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[{"id":"https://openalex.org/G1826404230","display_name":null,"funder_award_id":"RR 024148","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G562107762","display_name":"Center for Clinical and Translational Sciences","funder_award_id":"UL1RR024148","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2168026945.pdf","grobid_xml":"https://content.openalex.org/works/W2168026945.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W261844608","https://openalex.org/W1986561103","https://openalex.org/W1997983865","https://openalex.org/W2026408695","https://openalex.org/W2033564519","https://openalex.org/W2041030605","https://openalex.org/W2070900512","https://openalex.org/W2089484109","https://openalex.org/W2118778038","https://openalex.org/W2128879637","https://openalex.org/W2165275387","https://openalex.org/W2171799063","https://openalex.org/W2521973269","https://openalex.org/W3148486787","https://openalex.org/W4242006750"],"related_works":["https://openalex.org/W2033564519","https://openalex.org/W4234924147","https://openalex.org/W2514415225","https://openalex.org/W2171799063","https://openalex.org/W7095606996","https://openalex.org/W2110498792","https://openalex.org/W4391337903","https://openalex.org/W2328705550","https://openalex.org/W2887896395","https://openalex.org/W4384923046"],"abstract_inverted_index":{"Castleman's":[0],"disease":[1,80],"(CD)":[2],"is":[3,12],"a":[4,33,49,59,99],"very":[5],"rare":[6],"lymphoproliferative":[7],"disorder":[8],"whose":[9,79],"underlying":[10],"pathophysiology":[11],"not":[13],"fully":[14],"understood":[15],"and":[16,74,78,111,115,123],"for":[17,37,52,141],"which":[18],"no":[19],"standard":[20],"treatment":[21],"exists.":[22],"Because":[23],"interleukin-1":[24,45],"(IL-1)":[25],"might":[26],"promote":[27],"the":[28,38,44,56,92],"production":[29],"of":[30,58,85,102,126],"interleukin-6":[31],"(IL-6),":[32],"key":[34],"pathogenic":[35],"factor":[36],"disease,":[39],"we":[40],"hypothesized":[41],"that":[42,133],"blocking":[43],"receptor":[46,95],"would":[47],"be":[48,136],"useful":[50],"therapy":[51],"CD.":[53,144],"We":[54],"report":[55],"case":[57],"61-year-old":[60],"woman":[61],"with":[62],"CD":[63],"who":[64],"had":[65],"undergone":[66],"multiple":[67],"treatments,":[68],"including":[69,119],"cladribine,":[70],"rituximab,":[71],"steroids,":[72],"etanercept,":[73],"anti-IL-6":[75],"monoclonal":[76],"antibody,":[77],"was":[81,89],"refractory":[82,142],"to":[83],"all":[84,128],"these":[86],"treatments.":[87],"She":[88],"started":[90],"on":[91],"recombinant":[93],"IL-1":[94],"antagonist,":[96],"Anakinra,":[97],"at":[98],"subcutaneous":[100],"dose":[101],"100":[103],"mg":[104],"daily.":[105],"Within":[106],"one":[107],"week,":[108],"her":[109,116],"fatigue":[110],"anorexia":[112],"markedly":[113],"improved,":[114],"laboratory":[117],"abnormalities,":[118],"anemia,":[120],"thrombocytosis,":[121],"leukocytosis,":[122],"elevated":[124],"markers":[125],"inflammation,":[127],"resolved.":[129],"Our":[130],"observation":[131],"suggests":[132],"Anakinra":[134],"may":[135],"an":[137],"attractive":[138],"therapeutic":[139],"approach":[140],"multicentric":[143]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}